XL019 100mg 100mg | Purity Not Available
Adooq Bioscience
XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity.
More Information Supplier PageXL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity.
More Information Supplier PageXL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity.
More Information Supplier PageAZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
More Information Supplier PageAZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
More Information Supplier PageAZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
More Information Supplier PageAZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
More Information Supplier PageAZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
More Information Supplier PageClavulanic acid is a mechanism-based ??-lactamase inhibitorcombined with penicillin group antibiotics to overcome certain types of antibiotic resistance.
More Information Supplier PageClavulanic acid is a mechanism-based ??-lactamase inhibitorcombined with penicillin group antibiotics to overcome certain types of antibiotic resistance.
More Information Supplier PageClavulanic acid is a mechanism-based ??-lactamase inhibitorcombined with penicillin group antibiotics to overcome certain types of antibiotic resistance.
More Information Supplier Page